Member Info for crumbs

Yes, on one the one hand we can say this is the best possibly once in a lifetime opp ever to buy scancell so cheaply on the other we have no idea what the next RNS will be :) and it might not be the transformational one we know is possible scancell huh ! Who would be in it who would be out of it!

Surely... going by knowlesi's algorithms the 'big sells'(presumably ii) would have tanked sp to 3p by now... we know if it were pi selling such amounts it would have ... I dunno but seems some changing of hands has been going on...

BioNtech did a deal with Lilly in 2015 to find TCR targets(money attached the kind of money that transforms scancell)... nothing... none!... collab with scancell to find TCR targets... last I heard going great the initial collab to find TCR candidates from human blood ends H1 2019... so .. knowlesi and Tommys market raising at 4p... scancell not seeming too bothered no RNS hyping ... nothing... or something else?...

So now it is who else is playing with moditope?... BioNtech ... the Swedes gave the greenlight and yeah no commercial attached there... but BioNtech it is all about getting their TCR ready for IPO

I like this... The Swedes got to play with moditope then they extended their playtime and then they gave Lindy an award.... copyright team ramp 2019 :)

The story of today.

Should of added the Swedes got to play with moditope then extended their playtime :).... it is special... who else see's it?

Multiple partnership talks...
BioNtech collab is using human donated blood... the moditope mechanism works the only question is as Lindy says... will it be extraordinary or will it be small we hope it will be significant....it will have an effect... any deal with BioNtech not only gives valuation but huge validation... Sahin he says yes!... would expect our upmarket neighbours Immunocore and Adaptimmune to get all friendly

Scancell would not do an OO... it would not be cost effective and too risky.. if anything would be a placing ... as of yet nothing maybe that is because funding is coming from elsewhere... The Swedes got to play with moditope... Lindy gets an award... BioNtech got to play with moditope... hmm

On numbers I noticed there are more cases of head and neck cancer than sarcomas... not sure if this is behind the modi1 switch ...it still puzzles me... if it were a case of a third party wants it then surely it would have been added as an extra target with sarcomas still there... then again third party could be happy with the other two but wants head and neck too...all a mystery yet to be solved

lol doubt it ... it is to cancel brexit.. nana's nightmare!....

It's blown up the internet lol
https://www.wired.co.uk/article/revoke-article-50-petition

Fastest growing petition of all time ...revoke article 50 ...

Anyways ... should never ever write 'no deal 'on scancell BB :) ... against all team ramp rules!

Next pink floyd tweet we want.... Money! :)

I think the links you gave before are for a different award but named after the same guy:)

Here is where Lindy is today

http://onkologidagarna.se/2019program

Here is Lindy and other honorary lecturers

http://onkologidagarna.se/hedersforelasare

You need to know Swedish or like me use translate to understand anything :)

I think Lindy has won this and been invited due to her work with Karolinska ....

Hers is the last presentation and she gets a whole hour!

Lindy and other honorary lecturers..

http://onkologidagarna.se/hedersforelasare

You

Done Lindy... karolinska know moditopes potential will market wake up to it too

Jeez C7 has gone from a fighting cockerel to a mother hen!

Thanks Ruck...Doubt scancell will ever ge to the point to be valued by your formula unless it does indeed become a biopharma itself but show's the potential here....3 platforms multiple products many target's at many disease stages..

Hi.. it was just from that link I gave you and was verry hypothetical .... I just said if you went of those figures alone nothing else share issue exactly the same.. no ImmunoBody no moditope ... just 2 commercial glycan MaBs what would your formula make our sp to be?

The figures....and I know scancell could not commercialise them themselves and would need successful trials first etc... but just play with it lol

'The top two lead mAbs, FG27 and FG88, could potentially treat 214,500 and 421,500 patients per annum based upon the % of tumours that express the target antigen. These are patients who currently have failed all other therapies and die of their disease. If we assume market penetration of 50% and a treatment price of £10,000 per patient this is a potential market of £1-2 billion.

Patient Benefit
Our mAbs can be used in the treatment of a wide range of cancer patients. As they not only directly kill tumours but initiative immune responses they should confer similar survival benefits to the new checkpoinhibitors which are currently curing 20-50% of advanced melanoma patients. If our mAbs are used to treat over 300,000 patients per annum and a conservative 20% are cured this could result in saving over 60,000 lives per annum.'

Your best mates dad is not lying ;)

At least now buys are buys and sells are sells...

To be honest I would have thought it would have been busier on here today... a bit more input from doomers :) sadly not!... to me this RNS seems to be one for us and one scancell were not that bothered about putting out... now that can say many things but a 4p market raising?... in my opinion nope...